News | June 16, 2025
AstraZeneca collaborates with CSPC Pharmaceuticals focused on AI-enabled research
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,
Globally, BRUKINSA is approved in more than 70 countries
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP) companion diagnostic (CDx) toward potential FDA approval
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
First pivotal Phase 3 trial to show superiority of Keytruda plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC
Subscribe To Our Newsletter & Stay Updated
